Hims & Hers (HIMS) stock tanked on July 24 after an FDA advisory panel declined to recommend adding emideltide to the agency’s 503A Bulks List, which governs which substances licensed U.S. pharmacies may use to compound custom peptide treatments.
The same panel had voted narrowly in favor of four other peptides’ (including BPC-157) addition to the list, sending HIMS up more than 10%, but the emideltide rejection “renewed doubts” about the regulatory path for its peptide business.
